missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. Novus Biologicals™ IL-13 Antibody (CNTO 607), Novus Biologicals™
  7. 30044771

Novus Biologicals™ IL-13 Antibody (CNTO 607), Novus Biologicals™

Human Monoclonal Antibody

Brand:  Novus Biologicals™ NBP3-28181-50ug

 View more versions of this product

Product Code. 30044771

  • 213.00€ / 50µg

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

IL-13 Monoclonal antibody specifically detects IL-13 in Human samples. It is validated for Flow Cytometry,ELISA,Functional Assay
TRUSTED_SUSTAINABILITY
Specifications

Specifications

IL-13
Monoclonal
Unconjugated
P35225
Human
Protein A purified
RUO
Primary
Reconstitute with sterile, distilled water to a final concentration of 1 mg/mL. Gently shake to solubilize completely. Do not vortex.
Store at -20°C in powder form. Store at -80°C once reconstituted.
IgG1
Flow Cytometry, ELISA, Functional Assay
CNTO 607
Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
ALRHMGC116789, BHR1interleukin-13, IL-13MGC116788, interleukin 13, MGC116786, NC30, P600
IL-13
50 μg
Asthma, Biologically Active Proteins, Cancer, Cytokine Research, Immunology, Innate Immunity
3596
Human
Purified
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.